Lovenox Discontinued Promotions Are “False,” But Corrective Ads Not Warranted – Court
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis’ claims that enoxaparin is “therapeutic from dose one” and “reaches therapeutic levels within ½ hour” are unsupported. However, the claim that Lovenox requires “no routine monitoring” is not literally false, the court says.
You may also be interested in...
Lovenox Marketing Documents Subpoenaed By Chicago U.S. Attorney
Sanofi-Aventis is responding to a subpoena issued by the Chicago U.S. Attorney regarding "sales and marketing practices" for the low molecular weight heparin product Lovenox, the company disclosed Oct. 21
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.